Menu
Search
|

Menu

Close
X

Rigel Pharmaceuticals Inc RIGL.OQ (NASDAQ Stock Exchange Global Select Market)

3.70 USD
-0.08 (-2.12%)
As of 3:59 PM EST
chart
Previous Close 3.78
Open 3.83
Volume 212,069
3m Avg Volume 431,454
Today’s High 3.89
Today’s Low 3.69
52 Week High 4.71
52 Week Low 2.15
Shares Outstanding (mil) 146.49
Market Capitalization (mil) 553.74
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.83 Mean rating from 6 analysts

KEY STATS

Revenue (mm, USD)
FY17
4
FY16
20
FY15
29
EPS (USD)
FY17
-0.433
FY16
-0.734
FY15
-0.582
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
34.75
Price to Sales (TTM)
vs sector
73.99
8.23
Price to Book (MRQ)
vs sector
8.37
5.26
Price to Cash Flow (TTM)
vs sector
--
26.16
Total Debt to Equity (MRQ)
vs sector
0.00
15.44
LT Debt to Equity (MRQ)
vs sector
0.00
12.05
Return on Investment (TTM)
vs sector
-108.99
13.63
Return on Equity (TTM)
vs sector
-110.90
15.25

EXECUTIVE LEADERSHIP

Raul Rodriguez
President, Chief Executive Officer, Director, Since 2014
Salary: $551,720.00
Bonus: --
Dolly Vance
Executive Vice President, Corporate Affairs, General Counsel and Corporate Secretary, Since 2010
Salary: $475,548.00
Bonus: --
Eldon Mayer
Executive Vice President, Chief Commercial Officer, Since 2016
Salary: --
Bonus: --
Anne-Marie Duliege
Chief Marketing Officer, Since 2016
Salary: --
Bonus: --
Nelson Cabatuan
Interim Principal Accounting, Since 2017
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

1180 Veterans Blvd
SOUTH SAN FRANCISCO   CA   94080-1985

Phone: +1650.6241100

Rigel Pharmaceuticals, Inc. is a clinical-stage biotechnology company. The Company is engaged in the discovering, developing and providing novel small molecule drugs that improve the lives of patients with immune and hematological disorders, cancer and rare diseases. The Company’s pioneering research focuses on signaling pathways that are critical to disease mechanisms. The Company’s clinical programs include clinical trials of fostamatinib, an oral spleen tyrosine kinase (SYK) inhibitor, in a number of indications. The Company has submitted a new drug application (NDA) to the United States food and drug administration (FDA) for fostamatinib in patients with chronic or persistent immune thrombocytopenia (ITP). In addition, the Company has product candidates in development with partners BerGenBio AS, Daiichi Sankyo and Aclaris Therapeutics. The Company is engaged in conducting research in the disease areas of inflammation/immunology and muscle wasting/muscle endurance.

SPONSORED STORIES